Global Dry Eye Medication Market Opportunities and Strategies (2019 to 2030) – COVID-19 Impact and Recovery

May 28, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Dry Eye Medication Global Market Opportunities and Strategies to 2030: COVID 19 Impact and Recovery” report has been added to’s offering.

This report provides the strategists, marketers and senior management with the critical information they need to assess the global dry eye medication market as it emerges from the COVID 19 shut down.

The global dry eye medication market is expected to decline from $3,727.5 million in 2019 to $2919.9 million in 2020 at a compound annual growth rate (CAGR) of -22%. The decline is mainly due to economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 6.5% from 2021 and reach $5,047.9 million in 2023. The market is expected to grow at a CAGR of 7.1% to nearly $5,794.7 million by 2025, and at a CAGR of 6.9% to $8,078.4 billion by 2030.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Gain a global perspective on the development of the market.

This report describes and evaluates the global dry eye medication market. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.

Growth in the historic period resulted from an aging population, a rising number of contact lens users, and an increase in disposable income, increase in the number of treatment options and an increased number of allergies. Factors that negatively affected growth in the historic period were low healthcare access and a lack of awareness of the dry eye medication products amongst the common population.

The global ophthalmology drugs market, of which the dry eye medication market is a segment, reached a value of nearly $24,640.0 million in 2019, growing at a compound annual growth rate (CAGR) of 6.5% since 2015. It is expected to grow at a CAGR of 7.8% and reach nearly $33,272.8 million by 2023.

The dry eye medication market size will gain the most in the USA at $336.7 million. Market-trend-based strategies for the dry eye medication market include investing in research and development of new and advanced drugs, develop innovative drugs to survive in the market, develop non-steroidal anti-inflammatory ophthalmic drugs for the treatment of dry eye syndrome, and develop combination therapies for the treatment of dry eye diseases. Player-adopted strategies in the dry eye medication market include expanding through acquisitions, expanding through building diverse dry eye medication portfolio and launching new innovative drugs.

The outbreak of coronavirus has caused a shortage in the supply of essential eye medications for the treatment of dry eyes. This is because the COVID-19 pandemic created disruption in the global pharmaceutical supply chain which is heavily dependent on China. The main raw materials in the drug production are manufactured in China and are exported to other parts of the world after making the final drug. This has resulted in pharmacies and wholesalers reporting many drugs being out of stock.

Key Topics Covered:

1. Dry Eye Medication Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

7. Dry Eye Medication Market Characteristics

8. Dry Eye Medication Market Product Analysis – Product Examples


10. Dry Eye Medication Market Supply Chain Analysis

11. Dry Eye Medication Market Customer Information

12. Dry Eye Medication Market Trends And Strategies

13. Prevalence Of Dry Eye Disease

14. Impact Of COVID-19 On Dry Eye Medication Market

15. Unmet Needs In Dry Eye Medication Market

16. Dry Eye Medication Market, Pricing Analysis

17. Overview On Dry Eye Disease, Symptoms, And Line Of Treatment Options

18. Global Dry Eye Medication Market Size And Growth

19. Dry Eye Medication Market, Regional And Country Analysis

20. Global Dry Eye Medication Market Segmentation

21. Global Dry Eye Medication Market Comparison with Macro Economic Factors

Companies Mentioned

  • Adcock Ingram
  • Aflofarm Farmacja Polska Sp. z o. o
  • Aurinia Pharmaceuticals Inc
  • Bayer AG
  • Biolab Farmaceutica
  • Daiichi Sankyo
  • Endo International plc
  • ERC Labs
  • Gama Vision
  • Herzig Eye Institute
  • Horus Pharma
  • Implandata ophthalmic
  • Johnson & Johnson
  • Medicom Health care
  • Mitotech
  • Novaliq GmbH
  • Novamedika
  • Pfizer
  • Prestige Consumer Healthcare, Inc
  • Regenerx Biopharmaceuticals Inc
  • ReGenTree, LLC
  • Roche
  • Santen Pharmaceutical
  • Shanghai Pharmaceuticals
  • Shire
  • Similasan
  • Sun Pharma
  • The Geuder Group
  • Thomas Eye Group
  • Vision gain
  • VISUfarma
  • VUAB Pharma, Inc

For more information about this report visit


Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900